JANX
Work Here?
Overview
About JANX
Simplify's Rating
Why JANX is rated
B
Rated B on Competitive Edge
Rated B on Growth Potential
Rated B on Differentiation
Industries
Consulting
Industrial & Manufacturing
Company Size
51-200
Company Stage
N/A
Total Funding
N/A
Headquarters
Parma, Ohio
Founded
1981
Get referred to JANX
See people who can refer or advise you
Simplify's Take
What believers are saying
- Janux ended March 2026 with $956.4 million cash and short-term investments.
- Q1 2026 collaboration revenue reached $3.7 million after the BMS agreement.
- JANX007, JANX011, JANX014, and planned JANX013 each create multiple 2026 catalysts.
What critics are saying
- William Go exited as CMO on June 23, 2026; clinical execution now lacks a permanent leader.
- JANX008 was discontinued in April 2026 after Phase 1a, showing pipeline attrition.
- If JANX007 or JANX014 disappoint, Janux’s platform thesis and BMS validation weaken fast.
What makes JANX unique
- Janux’s TRACTr masking platform targets tumor enzymes, aiming for lower systemic T-cell toxicity.
- Bristol Myers Squibb licensed a Janux solid-tumor program in January 2026.
- Janux keeps advancing multiple modalities: TRACTr, TRACIr, and ARM.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
There are no jobs for JANX right now.
Find jobs on Simplify and start your career today
We update JANX's jobs every few hours, so check again soon! Browse all jobs →
About JANX
Simplify's Rating
Why JANX is rated
B
Rated B on Competitive Edge
Rated B on Growth Potential
Rated B on Differentiation
Industries
Consulting
Industrial & Manufacturing
Company Size
51-200
Company Stage
N/A
Total Funding
N/A
Headquarters
Parma, Ohio
Founded
1981
There are no jobs for JANX right now.
Find jobs on Simplify and start your career today
We update JANX's jobs every few hours, so check again soon! Browse all jobs →